Curcumin Supplement Registration in the UAE: A Worked Example from Formula to Dossier

About this worked example

This is a labelled worked example, not a client case study. The brand, the brief and every number on this page are assumptions or calculations from those assumptions. No client data, measured results or approval outcome are reported. It shows how Food Research Lab would plan curcumin supplement registration in the UAE, using Dubai Municipality’s health-supplement guideline^[1], the Emirates Drug Establishment (EDE) marketing-authorisation requirements^[2] and published curcumin pharmacokinetic studies^[3][4][5].

For other labelled worked examples, see our ashwagandha root extract capsule and vitamin D3 supplement case studies.

The brief: a curcumin capsule for UAE adults

A brand wants a once-daily curcumin capsule for adults in the UAE, sold through pharmacies and online. It wants an enhanced-absorption format and a general well-being claim, and it wants the product registrable before it commits to a supplier. Survey data suggest a sizeable market: 47.8% of 600 adults in a 2026 UAE survey had ever used dietary supplements, and 98.7% of 448 adults in a 2022 online survey reported using herbal medicines, although both used convenience samples^[6][7].

Table 1. Worked-example brief (all values assumed)

Step 1: classify the product and choose the route

Classification decides the rules, so it comes before formulation. Dubai Municipality’s guideline (Version 2, 4 May 2024) treats botanicals and herbs in capsules, tablets, powders and liquids as health supplements, provided they are not intended to treat, diagnose, prevent or cure disease. It places Ayurvedic, Chinese medicine and traditional medicine products outside that category^[1]. A turmeric extract capsule with a well-being claim fits the health-supplement definition; the same product sold as an Ayurvedic remedy or with a joint-disease claim would not.

The guideline’s Annex 3 lists banned ingredients. Curcuma longa and Piper nigrum are not on it, but several herbs often blended with turmeric are, including ashwagandha, shilajit and Terminalia arjuna^[1]. Any change to the formula therefore goes back through this check.

Table 2. Two UAE registration routes for this product

Which route applies depends on the product and the emirates where it will be sold, so we confirm the pathway with the authority before the dossier is built. Our guide to herbal supplement claims in the UAE covers the claim side of that decision.

Step 2: choose the absorption format on evidence

Curcumin is poorly absorbed, and the evidence for each enhanced format is narrower than marketing suggests:

• Piperine. In a 1998 study, 2 g of curcumin alone gave undetectable or very low serum levels in volunteers; adding 20 mg of piperine increased bioavailability by 2000%^[3].
• Phospholipid complex. In a randomised crossover study, total curcuminoid absorption was about 29-fold higher for a lecithin formulation than for the unformulated mixture, but only phase-2 metabolites were detected in plasma^[4].
• Independent reappraisal. A 2025 crossover study in nine healthy men found unconjugated curcumin below 2 nM in most cases, even at high dose with piperine; piperine gave no benefit, and the authors concluded that bioavailability claims should be based on unconjugated curcumin, not its conjugates^[5].

A 2023 review of clinical trials reaches a similar view: formulations differ widely, and results depend on what is measured^[8]. The team therefore shortlists both routes and makes no absorption claim unless finished-product pharmacokinetic data, with the analyte stated, support it. The science behind each format is set out in our cluster guide to curcumin bioavailability.

Safety belongs in the same decision. In August 2023 Australia’s Therapeutic Goods Administration (TGA) warned that turmeric and curcumin products may rarely cause liver injury, after 18 reports up to 29 June 2023, one of them fatal, and said the risk may be higher for products with enhanced bioavailability or higher doses^[9]. The dossier’s safety section should address this.

Table 3. Format comparison for this brief

Step 3: fix the dose and fill weight

The dose comes first. With a declared 400 mg of curcuminoids a day and an extract assayed at 95% curcuminoids, the extract needed is 400 ÷ 0.95 ≈ 421 mg a day, or about 211 mg per capsule at two capsules a day (Table 4). A phospholipid complex carries much less curcuminoid per gram, so the same declared dose needs a heavier fill; if the complex were 20% curcuminoids (assumed), the daily fill would be 400 ÷ 0.20 = 2,000 mg, which would force more capsules or a lower declared dose.

Table 4. Fill calculation (assumed values, not client data)

The daily intake also sets the contaminant budget. Dubai Municipality’s adult limits are per day: 20 µg lead, 6 µg cadmium, 10 µg arsenic and 20 µg mercury^[1]. At about 0.42 g of extract a day, the lead limit allows up to roughly 47 ppm in the extract; at 2 g of complex, roughly 10 ppm. The heavier the fill, the tighter the specification. How lead and undeclared drugs lead to recalls is covered in our herbal supplement recalls analysis.

Step 4: plan stability for hot, humid storage

Storage in the Gulf is hot, and the dossier needs stability data that reflect it. WHO stability guidance defines long-term conditions of 30 °C/65% RH (zone IVa) and 30 °C/75% RH (zone IVb), with 40 °C/75% RH for accelerated studies^[10]. The worked-example plan uses three batches in the final pack, long-term storage at 30 °C/75% RH with pulls at 0, 3, 6, 9, 12, 18 and 24 months, and accelerated storage at 40 °C/75% RH for six months (assumed design).

Each pull checks curcuminoid assay against the label, appearance and moisture, and selected pulls check microbiology against Dubai Municipality’s Annex 2 limits for herbal products: E. coli, Staphylococcus aureus and Salmonella absent, yeasts and moulds up to 1,000 CFU/g, aerobic bacteria up to 100,000 CFU/g and coliforms up to 10 CFU/g^[1]. Release and end-of-shelf-life targets follow the logic in our guide to supplement label claims and overage in the UAE.

Step 5: build the curcumin supplement registration dossier

Dubai Municipality’s guideline lists the documents for a health-supplement dossier, and the EDE lists its own^[1][2]. In this example, each document maps to a workstream already running (Figure 1):

Table 5. Dossier documents and where they come from

Registration is a documented workflow, not a guarantee of approval.

Step 6: label, claims and halal

Dubai Municipality requires the label to show, in English and/or Arabic, the brand and product names, manufacturer, country of origin, ingredients with botanical names, pack size, production and expiry dates, storage conditions, daily dose, intended use, a health warning and the batch number^[1]. Structure/function claims must be substantiated by ingredient-based evidence and, when necessary, product-based evidence. Annex 4 prohibits disease claims, including musculoskeletal and anti-inflammatory claims, and words such as “Effective” and “Anti-aging”^[1]. For curcumin, that rules out joint-disease and anti-inflammatory wording; a statement that the product is better absorbed is a product claim that needs product-based data. Advertising, including social media, needs pre-approval through Montaji^[1].

Halal status is documented in the file: a gelatin capsule needs a halal certificate for its animal source, while an HPMC capsule avoids the animal-source question^[1][2].

What the worked example shows

It shows sequence rather than outcome. Classifying the product, fixing the dose and fill, setting the contaminant budget, planning stability and agreeing claim wording before the dossier is assembled means no step reopens another. It also shows where evidence is needed: an enhanced-absorption claim needs finished-product pharmacokinetic data, while a well-being claim on a correctly classified product needs far less.

• Classify first, and recheck Annex 3 whenever the formula changes^[1].
• Let the evidence set the claim: published absorption gains depend on the formulation and the analyte measured^[4][5].
• Recalculate fill weight and metal limits whenever the supplier, assay or format changes.
• Plan stability at 30 °C/75% RH in the final pack^[10].
• Keep label and advertising matched to the registered file.

For brands & formulators

Food Research Lab, based in Chennai, India, helps brands take herbal supplements such as curcumin capsules from brief to a UAE-ready file. Our herbal formulation team selects the format, fixes dose and fill weight and writes the specifications. Our regulatory and scientific research team classifies the product, checks claims and prepares the dossier for Dubai Municipality or the EDE. Shelf-life studies, curcuminoid assays and heavy-metal testing are run or arranged through accredited partner laboratories. See also our UAE services.

Contact us with your brief, target dose and markets.

In this series

• Herbal supplement demand in the UAE: who is buying herbal and Ayurvedic supplements in the UAE and GCC.
• Curcumin bioavailability: the science of absorption formats, including turmeric with black pepper (cluster guide).
• Herbal supplement claims in the UAE: what the rules allow on labels and in advertising.
• Herbal extraction methods compared: maceration to supercritical CO₂.
• Herbal supplement recalls: what lead and undeclared drugs in Ayurvedic products reveal.
• Curcumin supplement registration in the UAE: a worked example from formula to dossier (you are here).
• Herbal formulations: FRL’s herbal product development service.

1. Dubai Municipality. (2024, May 4). Technical guidelines for health supplements (DM-HSD-GU29-TGHS2, Version 2.0). https://dmpmedia.dm.gov.ae/uploads/2024/07/DM-HSD-GU29-TGHS2_Technical-Guidelines-for-Health-Supplements_V2.pdf (cited for scope and exclusions in §5, safety requirements in §6, label and claim rules in §7, Montaji registration and validity in §8, dossier documents in §9, advertising approval in §11.2, Annex 2 microbial and heavy-metal limits, Annex 3 banned ingredients and Annex 4 prohibited claims)
2. Emirates Drug Establishment. (n.d.). Issuance of marketing authorization for a healthcare product. Retrieved 11 November 2026, from https://www.ede.gov.ae/en/w/issuance-of-marketing-authorization-for-a-healthcare-product (cited for scope, required documents including the halal certificate and harmful-substances statement, 45 working days, fees and 5-year validity)
3. Shoba, G., Joy, D., Joseph, T., Majeed, M., Rajendran, R., & Srinivas, P. S. (1998). Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Medica, 64(4), 353–356. https://doi.org/10.1055/s-2006-957450 (cited for the 2000% increase in bioavailability with 20 mg piperine and 2 g curcumin)
4. Cuomo, J., Appendino, G., Dern, A. S., Schneider, E., McKinnon, T. P., Brown, M. J., Togni, S., & Dixon, B. M. (2011). Comparative absorption of a standardized curcuminoid mixture and its lecithin formulation. Journal of Natural Products, 74(4), 664–669. https://doi.org/10.1021/np1007262 (cited for about 29-fold higher total curcuminoid absorption, detected only as phase-2 metabolites)
5. Kroon, M. A. G. M., van Laarhoven, H. W. M., Swart, E. L., van Tellingen, O., & Kemper, E. M. (2025). A pharmacokinetic study and critical reappraisal of curcumin formulations enhancing bioavailability. iScience, 28(6), 112575. https://doi.org/10.1016/j.isci.2025.112575 (cited for the nine-subject crossover, unconjugated curcumin below 2 nM, no benefit from piperine and basing claims on unconjugated curcumin)
6. Alkhayat, A., & Khan, N. S. (2026). Prevalence, patterns, perceptions, and sociodemographic determinants of dietary supplement use among adults in the United Arab Emirates. Frontiers in Nutrition, 13, 1955988. https://doi.org/10.3389/fnut.2026.1955988 (cited for 47.8% of 600 adults having ever used dietary supplements; convenience sample)
7. Al Mazrouei, N., Al Meslamani, A. Z., Alajeel, R., Alghadban, G., Ansari, N., Al Kaabi, M., Sadeq, A., Ibrahim, R., & Ibrahim, O. M. (2022). The patterns of herbal medicine use in the United Arab Emirates; A national study. Pharmacy Practice, 20(3), 2698. https://doi.org/10.18549/PharmPract.2022.3.2698 (cited for 98.7% of 448 adults reporting herbal medicine use; online convenience sample)
8. Hegde, M., Girisa, S., BharathwajChetty, B., Vishwa, R., & Kunnumakkara, A. B. (2023). Curcumin formulations for better bioavailability: What we learned from clinical trials thus far? ACS Omega, 8(12), 10713–10746. https://doi.org/10.1021/acsomega.2c07326 (cited for the range of curcumin formulations tested in clinical trials)
9. Therapeutic Goods Administration. (2023, August). Medicines containing turmeric or curcumin: risk of liver injury [Safety alert]. https://www.tga.gov.au/safety/safety-alerts/medicines-containing-turmeric-or-curcumin-risk-liver-injury (cited for 18 liver injury reports up to 29 June 2023, one fatal, and possible higher risk with enhanced-bioavailability or higher-dose products)
10. World Health Organization. (2018). WHO guidelines on stability testing of active pharmaceutical ingredients and finished pharmaceutical products. In WHO Expert Committee on Specifications for Pharmaceutical Preparations: Fifty-second report (WHO Technical Report Series, No. 1010, Annex 10). https://www.who.int/publications/m/item/trs1010-annex10 (cited for zone IVa 30 °C/65% RH, zone IVb 30 °C/75% RH and accelerated 40 °C/75% RH conditions)